English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The cyclical rise, fall and resurrection of thalidomide has become one of the most instructive stories in medicine, told most poignantly by Stephens and Brynner1 in their recent book. In the early 1950s, when pathogens were considered to be the primary causative agents of most human diseases, two chemists working for the pharmaceutical company Chemie Grunenthal heated the peptide pthalimidoglutaramide in an attempt to synthesize novel antibiotics. They obtained a compound with a three-ring structure, which they named thalidomide.

The third coming: Thalidomide and a final goodbye